July 30, 2014
Campath-Based Tx Lowers Risk of Kidney Rejection
There are a lot of regimens being tried in transplant, and most include calcineurin inhibitors that have significant toxicity," Anupam Agarwal, MD, of the University of Alabama at Birmingham, told MedPage Today. "Hence, if one could safely reduce the dose of the calcineurin inhibitor and still benefit from its immunosuppressive properties, it would be huge advance."
- Alternate Title Link: http://www.medpagetoday.com/Nephrology/KidneyTransplantation/46981